ABBVIE

Trogenix has appointed Atif Abbas, MD as Chief Medical Officer, bringing over 25 years of oncology drug development experience including successful IND submissions for immunotherapy compounds and regulatory approvals.

The NHS in England has approved relugolix combination therapy as the first long-term daily oral treatment for endometriosis, expected to benefit around 1,000 women annually whose symptoms persist despite previous treatments.

Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.

Oxford BioTherapeutics announced that Boehringer Ingelheim has selected a third drug candidate targeting OB33 to advance into IND-enabling studies under their ongoing collaboration.

Neurocrine Biosciences initiated Phase 1 trials for NBIP-01435, a long-acting injectable CRF1 receptor antagonist for congenital adrenal hyperplasia (CAH), complementing its recently approved oral therapy CRENESSITY.

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist for congenital adrenal hyperplasia treatment.

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1 billion to gain access to CPTX2309, a potential first-in-class treatment for autoimmune diseases currently in Phase 1 trials.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Allergan Aesthetics has received FDA acceptance for review of its supplemental premarket approval application to expand SKINVIVE by Juvéderm's indication from cheek smoothness to include neck line treatment.

Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.